Back to results
US 7,402,312 B2Granted
Antibodies to vascular endothelial growth factor 2 (VEGF-2)
AssigneeHuman Genome Sciences, Inc.
InventorsCraig A. Rosen, Vivian R. Albert, Steven M. Ruben, Ruth E. Wager
Life of this patent
Estimating the term…
Abstract
Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention also relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.
Claims36
A pharmaceutical composition comprising:
- (a) a first antibody that specifically binds a VEGF-2 polypeptide, said antibody comprising an amino acid sequence that is at least 95% identical to an amino acid sequence selected from the group consisting of:
- (i) the amino acid sequence of the VH domain of the antibody expressed by the hybridoma cell line deposited under ATCC™ Deposit No. PTA-3341 or PTA-3342;
- (ii) the amino acid sequence of the VL domain of the antibody expressed by the hybridoma cell line deposited under ATCC™ Deposit No. PTA-3341 or PTA-3342;
- (iii) both (i) and (ii);
- (iv) the amino acid sequence of the VH domain of SEQ ID NO:76 or 78;
- (v) the amino acid sequence of the VL domain of SEQ ID NO:77 or 79;
- and
- (vi) both (iv) and (v);
- and
- (b) a pharmaceutically acceptable carrier.
7 more elements
A pharmaceutical composition comprising:
- (a) a first antibody selected from the group consisting of:
- (i) an antibody comprising a VH domain that comprises the amino acid sequence of the VH domain of the antibody expressed by the hybridoma cell line deposited under ATCC™ Deposit No. PTA-3341 and a VL domain that comprises the amino acid sequence of the VL domain of the antibody expressed by the hybridoma cell line deposited under ATCC™ Deposit No. PTA-3341;
- (ii) an antibody comprising a VH domain that comprises the amino acid sequence of the VH domain of the antibody expressed by the hybridoma cell line deposited under ATCC™ Deposit No. PTA-3342 and a VL domain that comprises the amino acid sequence of the VL domain of the antibody expressed by the hybridoma cell line deposited under ATCC™ Deposit No. PTA-3342;
- (iii) an antibody comprising a VH domain that comprises the amino acid sequence of SEQ ID NO:
- 76 and a VL domain that comprises the amino acid sequence of SEQ ID NO:77;
- and
- (iv) an antibody comprising a VH domain that comprises the amino acid sequence of SEQ ID NO:
- 78 and a VL domain that comprises the amino acid sequence of SEQ ID NO:79;
- and
- (b) a pharmaceutically acceptable carrier.
7 more elements
Dependencies are inferred from the claim text.